{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:16:10Z","timestamp":1789010170296,"version":"build-2803163510"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment of hypothyroidism with 3,5,3\u2032-triiodothyronine (T<jats:sub>3<\/jats:sub>) is controversial. A recent meta-analysis concludes that no evidence is present in favour of using T<jats:sub>3<\/jats:sub>. However, the analysis included a mixture of different patient groups and dose-regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the effect of combination therapy with thyroxine (T<jats:sub>4<\/jats:sub>) and T<jats:sub>3<\/jats:sub> versus T<jats:sub>4<\/jats:sub> monotherapy in patients with hypothyroidism on stable T<jats:sub>4<\/jats:sub> substitution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>Double-blind, randomised cross-over. Fifty micrograms of the usual T<jats:sub>4<\/jats:sub> dose was replaced with either 20\u200a\u03bcg T<jats:sub>3<\/jats:sub> or 50\u200a\u03bcg T<jats:sub>4<\/jats:sub> for 12 weeks, followed by cross-over for another 12 weeks. The T<jats:sub>4<\/jats:sub> dose was regulated if needed, intending unaltered serum TSH levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evaluation<\/jats:title><jats:p>Tests for quality of life (QOL) and depression (SF-36, Beck Depression Inventory, and SCL-90-R) at baseline and after both treatment periods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Inclusion criteria<\/jats:title><jats:p>Serum TSH between 0.1 and 5.0\u200amU\/l on unaltered T<jats:sub>4<\/jats:sub> substitution for 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 59 patients (55 women); median age 46 years. When comparing scores of QOL and depression on T<jats:sub>4<\/jats:sub> monotherapy versus T<jats:sub>4<\/jats:sub>\/T<jats:sub>3<\/jats:sub> combination therapy, significant differences were seen in 7 out of 11 scores, indicating a positive effect related to the combination therapy. Forty-nine percent preferred the combination and 15% monotherapy (<jats:italic>P<\/jats:italic>=0.002). Serum TSH remained unaltered between the groups as intended.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a study design, where morning TSH levels were unaltered between groups combination therapy, (treated with T<jats:sub>3<\/jats:sub> 20\u200a\u03bcg once daily) was superior to monotherapy by evaluating several QOL, depression and anxiety rating scales as well as patients own preference.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-09-0542","type":"journal-article","created":{"date-parts":[[2009,8,8]],"date-time":"2009-08-08T00:44:45Z","timestamp":1249692285000},"page":"895-902","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":133,"title":["Effect of combination therapy with thyroxine (T4) and 3,5,3\u2032-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study"],"prefix":"10.1093","volume":"161","author":[{"given":"Birte","family":"Nygaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebbe Winther","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kvetny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jarl\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/161\/6\/895.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/161\/6\/895.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:23:48Z","timestamp":1676391828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/161\/6\/895\/6676176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":0,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/eje-09-0542","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}